Compare COLL & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COLL | STEW |
|---|---|---|
| Founded | 2002 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2015 | N/A |
| Metric | COLL | STEW |
|---|---|---|
| Price | $47.02 | $17.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $47.50 | N/A |
| AVG Volume (30 Days) | ★ 550.1K | 84.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | 1.44 |
| Revenue | ★ $757,067,000.00 | N/A |
| Revenue This Year | $26.35 | N/A |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $29.21 | ★ $10.34 |
| Revenue Growth | ★ 26.34 | N/A |
| 52 Week Low | $23.23 | $11.97 |
| 52 Week High | $49.09 | $14.94 |
| Indicator | COLL | STEW |
|---|---|---|
| Relative Strength Index (RSI) | 68.88 | 47.96 |
| Support Level | $46.81 | $17.96 |
| Resistance Level | $49.09 | $18.20 |
| Average True Range (ATR) | 1.33 | 0.18 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 69.59 | 39.73 |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.